Melinta Therapeutics, LLC announced that it has acquired the U.S. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc. TOPROL-XL®, approved by the FDA in 1992, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins. Melinta has begun the integration process to bring TOPROL-XL® into the company's existing production, distribution and commercialization structure to ensure this important medication will continue to be made available without interruption.
1st Jan change | Capi. | |
---|---|---|
+18.43% | 124B | |
+19.81% | 114B | |
-23.74% | 19.42B | |
-17.94% | 16.2B | |
-19.97% | 15.31B | |
-49.33% | 14.19B | |
+57.08% | 14.32B | |
+7.95% | 14.31B | |
+126.04% | 11.29B |